This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Partridge, A. H. Articles by Avorn, J. Search for Related Content PubMed PubMed Citation Articles by Partridge, A. H. Articles by Avorn, J. Social Bookmarking                            What's this?

Nonadherence to Adjuvant Tamoxifen Therapy in Women With Primary Breast Cancer

Ann H. Partridge, Philip S. Wang, Eric P. Winer, Jerry Avorn

From the Department of Medical Oncology, Dana-Farber Cancer Institute, Division of Pharmacoepidemiology and Pharmacoeconomics, and Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA.

Address reprint requests to Ann H. Partridge, MD, Dana-Farber Cancer Institute, 44 Binney St., D1210, Boston, MA 02115; email: ahpartridge{at}partners.org.

Purpose: Although clinical trials have clearly demonstrated the benefits of tamoxifen in women with primary breast cancer, little is known about how this drug is actually used in the general population. We sought to estimate adherence and predictors of nonadherence in women starting tamoxifen as adjuvant breast cancer therapy.

Patients and Methods: Subjects were age 18 years or older initiating tamoxifen for primary breast cancer and enrolled in New Jersey’s Medicaid or Pharmaceutical Assistance to the Aged and Disabled programs during the study period, from 1990 to 1996 (N = 2,378). Main outcome measures were number of days covered by filled prescriptions for tamoxifen in the first year of therapy with the 4 years after tamoxifen initiation for a subset; predictors of good versus poor adherence.

Results: Twenty-three percent of patients missed taking tamoxifen on more than one fifth of days studied, although on average, patients filled prescriptions for tamoxifen for 87% of their first year of treatment. The youngest, oldest, nonwhite, and mastectomy patients had significantly lower rates of adherence; patients who had seen an oncologist before taking tamoxifen had significantly higher rates of adherence. Overall adherence decreased to 50% by year 4 of therapy.

Conclusion: The mean level of adherence to tamoxifen is high compared with other chronic medications. However, nearly one fourth of patients may be at risk for inadequate clinical response because of poor adherence. Because of the efficacy of tamoxifen therapy in preventing recurrence and death in women with early-stage breast cancer, further efforts are necessary to identify and prevent suboptimal adherence.

This research was supported in part by a Training Grant in Epidemiology and Prevention of Breast Cancer through the U.S. Department of Defense (DAMD17-00-1-0165), a research grant from the National Institute on Aging (R03-AG18395), and the NCI Specialized Program of Research Excellence (SPORE) in breast cancer at the Dana-Farber Cancer Institute.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Costantini, A. Picardi, M. Zilli, F. Cairoli, R. Torta, P. Marchetti, W. Baile, and S. Iacobelli Discussion about switch strategy in the adjuvant hormonal therapy of breast cancer: psychological aspects of physician-patient communication Ann. Onc., October 1, 2009; 20(10): 1647 - 1652. [Abstract] [Full Text] [PDF]

				G. Kimmick, R. Anderson, F. Camacho, M. Bhosle, W. Hwang, and R. Balkrishnan Adjuvant Hormonal Therapy Use Among Insured, Low-Income Women With Breast Cancer J. Clin. Oncol., July 20, 2009; 27(21): 3445 - 3451. [Abstract] [Full Text] [PDF]

				K. S. Albain, J. M. Unger, J. J. Crowley, C. A. Coltman Jr, and D. L. Hershman Racial Disparities in Cancer Survival Among Randomized Clinical Trials Patients of the Southwest Oncology Group J Natl Cancer Inst, July 15, 2009; 101(14): 984 - 992. [Abstract] [Full Text] [PDF]

				A. DeMichele, R. Gray, M. Horn, J. Chen, R. Aplenc, W. P. Vaughan, and M. S. Tallman Host Genetic Variants in the Interleukin-6 Promoter Predict Poor Outcome in Patients with Estrogen Receptor-Positive, Node-Positive Breast Cancer Cancer Res., May 15, 2009; 69(10): 4184 - 4191. [Abstract] [Full Text] [PDF]

				D. L. Hershman, J. M. Unger, W. E. Barlow, L. F. Hutchins, S. Martino, C. K. Osborne, R. B. Livingston, and K. S. Albain Treatment Quality and Outcomes of African American Versus White Breast Cancer Patients: Retrospective Analysis of Southwest Oncology Studies S8814/S8897 J. Clin. Oncol., May 1, 2009; 27(13): 2157 - 2162. [Abstract] [Full Text] [PDF]

				V. Ziller, M. Kalder, U.-S. Albert, W. Holzhauer, M. Ziller, U. Wagner, and P. Hadji Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer Ann. Onc., March 1, 2009; 20(3): 431 - 436. [Abstract] [Full Text] [PDF]

				K. J. Ruddy and A. H. Partridge Adherence with adjuvant hormonal therapy for breast cancer Ann. Onc., March 1, 2009; 20(3): 401 - 402. [Full Text] [PDF]

				B. Seruga and I. F. Tannock Up-Front Use of Aromatase Inhibitors As Adjuvant Therapy for Breast Cancer: The Emperor Has No Clothes J. Clin. Oncol., February 20, 2009; 27(6): 840 - 842. [Full Text] [PDF]

				K. Ruddy, E. Mayer, and A. Partridge Patient adherence and persistence with oral anticancer treatment CA Cancer J Clin, January 1, 2009; 59(1): 56 - 66. [Abstract] [Full Text] [PDF]

				C. Magai, N. S. Consedine, B. A. Adjei, D. Hershman, and A. Neugut Psychosocial Influences on Suboptimal Adjuvant Breast Cancer Treatment Adherence Among African American Women: Implications for Education and Intervention Health Educ Behav, December 1, 2008; 35(6): 835 - 854. [Abstract] [PDF]

				D. L. Hershman Getting a Grip on Aromatase Inhibitor-Associated Arthralgias J. Clin. Oncol., July 1, 2008; 26(19): 3120 - 3121. [Full Text] [PDF]

				N. Farag, R. Burns, and S. E. Come Update: A 62-Year-Old Woman With a New Diagnosis of Breast Cancer JAMA, March 5, 2008; 299(9): 1055 - 1056. [Full Text] [PDF]

				P Hadji Menopausal symptoms and adjuvant therapy-associated adverse events Endocr. Relat. Cancer, March 1, 2008; 15(1): 73 - 90. [Abstract] [Full Text] [PDF]

				N. U. Lin and E. P. Winer Advances in Adjuvant Endocrine Therapy for Postmenopausal Women J. Clin. Oncol., February 10, 2008; 26(5): 798 - 805. [Abstract] [Full Text] [PDF]

				C. Owusu, D. S.M. Buist, T. S. Field, T. L. Lash, S. S. Thwin, A. M. Geiger, V. P. Quinn, F. Frost, M. Prout, M. U. Yood, et al. Predictors of Tamoxifen Discontinuation Among Older Women With Estrogen Receptor-Positive Breast Cancer J. Clin. Oncol., February 1, 2008; 26(4): 549 - 555. [Abstract] [Full Text] [PDF]

				A. H. Partridge, A. LaFountain, E. Mayer, B. S. Taylor, E. Winer, and A. Asnis-Alibozek Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer J. Clin. Oncol., February 1, 2008; 26(4): 556 - 562. [Abstract] [Full Text] [PDF]

				K. D. Crew, H. Greenlee, J. Capodice, G. Raptis, L. Brafman, D. Fuentes, A. Sierra, and D. L. Hershman Prevalence of Joint Symptoms in Postmenopausal Women Taking Aromatase Inhibitors for Early-Stage Breast Cancer J. Clin. Oncol., September 1, 2007; 25(25): 3877 - 3883. [Abstract] [Full Text] [PDF]

				C. S. Viele Managing oral chemotherapy: The healthcare practitioner's role Am. J. Health Syst. Pharm., May 1, 2007; 64(9_Supplement_5): S25 - S32. [Abstract] [Full Text] [PDF]

				A. B. Mariotto, E. J. Feuer, L. C. Harlan, and J. Abrams Chapter 2: Dissemination of Adjuvant Multiagent Chemotherapy and Tamoxifen for Breast Cancer in the United States Using Estrogen Receptor Information: 1975-1999 J Natl Cancer Inst Monographs, October 1, 2006; 2006(36): 7 - 15. [Abstract] [Full Text] [PDF]

				A. I. Neugut, M. Matasar, X. Wang, R. McBride, J. S. Jacobson, W.-Y. Tsai, V. R. Grann, and D. L. Hershman Duration of Adjuvant Chemotherapy for Colon Cancer and Survival Among the Elderly J. Clin. Oncol., May 20, 2006; 24(15): 2368 - 2375. [Abstract] [Full Text] [PDF]

				L. J. Fallowfield, J. M. Bliss, L. S. Porter, M. H. Price, C. F. Snowdon, S. E. Jones, R. C. Coombes, and E. Hall Quality of Life in the Intergroup Exemestane Study: A Randomized Trial of Exemestane Versus Continued Tamoxifen After 2 to 3 Years of Tamoxifen in Postmenopausal Women With Primary Breast Cancer J. Clin. Oncol., February 20, 2006; 24(6): 910 - 917. [Abstract] [Full Text] [PDF]

				A. H. Partridge Non-adherence to endocrine therapy for breast cancer Ann. Onc., February 1, 2006; 17(2): 183 - 184. [Full Text] [PDF]

				L. Fallowfield, L. Atkins, S. Catt, A. Cox, C. Coxon, C. Langridge, R. Morris, and M. Price Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer Ann. Onc., February 1, 2006; 17(2): 205 - 210. [Abstract] [Full Text] [PDF]

				A. K. Fink, J. Gurwitz, W. Rakowski, E. Guadagnoli, and R. A. Silliman Patient Beliefs and Tamoxifen Discontinuance in Older Women With Estrogen Receptor--Positive Breast Cancer J. Clin. Oncol., August 15, 2004; 22(16): 3309 - 3315. [Abstract] [Full Text] [PDF]